RNA, U2 small nuclear 25, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-25P profile across patient tissues and cancer cell-line models. RNU2-25P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RNU2-25P is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, RNU2-25P RNA expression shows 8,673 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight COAD, LUSC, and HNSC as cancer lineages where RNU2-25P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-25P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-25P survival associations across molecular data types. RNU2-25P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-25P RNA expression–survival associations across cancer types. High RNU2-25P expression shows unfavorable associations in COAD, LUSC, ESCA, SKCM, KIRP and DLBC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for RNU2-25P RNA expression.
This table summarizes RNU2-25P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-25P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-25P shows lower tumor expression in LUSC, KIRC, BRCA, KIRP and LUAD and higher tumor expression in STAD. The LUSC box plot shows higher RNU2-25P RNA expression in normal versus tumor tissue (log2 FC = −0.311, t-test p < 0.001).
This table shows molecular features associated with RNU2-25P in patient tissues and cancer cell lines. In patient samples, RNU2-25P shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
